Search for a doctor

Aaron S. Mansfield, M.D.

  1. Oncologist
Request an Appointment

Publications

  1. Mansfield AS, Vivien Yin J, Bradbury P, Kwiatkowski DJ, Patel S, Bazhenova LA, Forde P, Lou Y, Dizona P, Villaruz LC, Arnold SM, Khalil M, Kindler HL, Koczywas M, Pacheco J, Rolfo C, Xia B, Mikula E, Chen L, Patel K, Smith KER, Cao L, Shapiro G, Costello BA, Adjei A, Sharon E, Moscow JA, Zamboni W, Hassan R. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma. Lung Cancer. 2024 Sep; 195:107928 Epub 2024 Aug 13
    View PubMed
  2. Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E, Cicin I, Ciuleanu T, Daaboul N, Liu C, Bradbury P, Moskovitz M, Katgi N, Tomasini P, Zer A, Girard N, Cuppens K, Han JY, Wu SY, Baijal S, Mansfield AS, Kuo CH, Nishino K, Lee SH, Planchard D, Baik C, Li M, Ansell P, Xia S, Bolotin E, Looman J, Ratajczak C, Lu S. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial. J Clin Oncol. 2024 Sep 1; 42 (25):3000-3011 Epub 2024 June 06
    View PubMed
  3. Lee JY, Reyes N, Woo SH, Goel S, Stratton F, Kuang C, Mansfield AS, LaFave LM, Peng T. Senescent fibroblasts in the tumor stroma rewire lung cancer metabolism and plasticity. bioRxiv. 2024 Jul 30 Epub 2024 July 30
    View PubMed
  4. Parikh K, Dimou A, Leventakos K, Mansfield AS, Shanshal M, Wan Y, Lin HM, Vincent S, Elliott J, Bonta IR. Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database. J Thorac Oncol. 2024 Jul 15. [Epub ahead of print]
    View PubMed
  5. Blyth KG, Adusumilli PS, Astoul P, Darlison L, Lee YCG, Mansfield AS, Marciniak SJ, Maskell N, Panou V, Peikert T, Rahman NM, Zauderer MG, Sterman D, Fennell DA. Leveraging the pleural space for anticancer therapies in pleural mesothelioma. Lancet Respir Med. 2024 Jun; 12 (6):476-483 Epub 2024 May 10
    View PubMed
  6. Desai A, Xiao AH, Choi D, Toruner MD, Walden D, Halfdanarson TR, Alberts S, McWilliams RR, Mahipal A, Ahn D, Babiker H, Stybayeva G, Revzin A, Kizilbash S, Adjei A, Bekaii-Saab T, Mansfield AS, Carr RM, Ma WW. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2024 May 13; 16 (10)
    View PubMed
  7. Galeano B, Smith CJ, Yi ES, Roden AC, Jenkins S, Capelle J, Kittle-Francis M, Mansfield AS, Aubry MC. Ki-67 Proliferation Index Is Associated With Tumor Grade and Survival in Pleural Epithelioid Mesotheliomas. Am J Surg Pathol. 2024 May 01; 48(5):615-622. Epub 2024 Feb 19.
    View PubMed
  8. Tevaarwerk AJ, Karam D, Gatten CA, Harlos ES, Maurer MJ, Giridhar KV, Haddad TC, Alberts SR, Holton SJ, Stockham A, Leventakos K, Hubbard JM, Mansfield AS, Halfdanarson TR, Chen R, Jochum JA, Schwecke AS, Eiring RA, Carroll JL, Riaz IB, McWilliams RR, Galanis E, Mandrekar SJ. Transforming the oncology data paradigm by creating, capturing, and retrieving structured cancer data at the point of care: A Mayo Clinic pilot. Cancer. 2024 Apr 25 [Epub ahead of print]
    View PubMed
  9. Szlosarek PW, Creelan BC, Sarkodie T, Nolan L, Taylor P, Olevsky O, Grosso F, Cortinovis D, Chitnis M, Roy A, Gilligan D, Kindler H, Papadatos-Pastos D, Ceresoli GL, Mansfield AS, Tsao A, O'Byrne KJ, Nowak AK, Steele J, Sheaff M, Shiu CF, Kuo CL, Johnston A, Bomalaski J, Zauderer MG, Fennell DA, ATOMIC-Meso Study Group. Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial. JAMA Oncol. 2024 Apr 1; 10 (4):475-483
    View PubMed
  10. Saddoughi SA, Powell C, Stroh GR, Rajagopalan S, Bartholmai BJ, Boland JM, Aubry MC, Harmsen WS, Blackmon SH, Cassivi SD, Nichols FC, Reisenauer JS, Shen KR, Mansfield AS, Maldonado F, Peikert T, Wigle DA. Long-Term Survival and CANARY-Based Artificial Intelligence for Multifocal Lung Adenocarcinoma Mayo Clin Proc: Digital Health. 2024; 2(1):44-52.
  11. Griesinger F, Curigliano G, Subbiah V, Baik CS, Tan DS, Lee DH, Misch D, Garralda E, Kim DW, van der Wekken AJ, Gainor JF, Paz-Ares L, Liu SV, Kalemkerian GP, Bowles DW, Mansfield AS, Lin JJ, Smoljanovic V, Rahman A, Zalutskaya A, Louie-Gao M, Boral AL, Mazieres J. Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study. Future Oncol. 2024 Feb; 20 (6):297-306 Epub 2023 Nov 02
    View PubMed
  12. Subbiah V, Hu MI, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth L, Gainor JF, Alonso G, Adkins D, Godbert Y, Ahn MJ, Cassier PA, Cho BC, Lin CC, Zalutskaya A, Barata T, Trask P, Scalori A, Bordogna W, Heinzmann S, Brose MS. Pralsetinib in patients with advanced/metastatic rearranged during transfection (ret)-altered thyroid cancer: updated efficacy and safety data from the arrow study. Thyroid: Official Journal of the American Thyroid Association. 2024; 34 (1):26-40
  13. Subbiah V, Hu MI, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth L, Gainor JF, Alonso G, Adkins D, Godbert Y, Ahn MJ, Cassier PA, Cho BC, Lin CC, Zalutskaya A, Barata T, Trask P, Scalori A, Bordogna W, Heinzmann S, Brose MS. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2024 Jan; 34 (1):26-40
    View PubMed
  14. Sabari JK, Girard N, Mansfield AS, Sanborn RE, Agrawal T, Zhou C, Park K. Plain language summary of PAPILLON: amivantamab plus chemotherapy in untreated EGFR-mutated non-small-cell lung cancer. Future Oncol. 2024; 20 (32):2409-2421 Epub 2024 July 16
    View PubMed
  15. Burns L, Hsu CY, Whisenant JG, Marmarelis ME, Presley CJ, Reckamp KL, Khan H, Jo Fidler M, Bestvina CM, Brahmer J, Puri S, Patel JD, Halmos B, Hirsch FR, Liu SV, Costa DB, Goldberg SB, Feldman LE, Mamdani H, Puc M, Mansfield AS, Islam N, Scilla KA, Garassino MC, Horn L, Peters S, Wakelee HA, Charlot M, Tapan U. Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT). Lung Cancer. 2023 Dec; 186:107423 Epub 2023 Nov 13
    View PubMed
  16. Liu SV, Mok TSK, Nabet BY, Mansfield AS, De Boer R, Losonczy G, Sugawara S, Dziadziuszko R, Krzakowski M, Smolin A, Hochmair MJ, Garassino MC, Gay CM, Heymach JV, Byers LA, Lam S, Cardona A, Morris S, Adler L, Shames DS, Reck M. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide. Lung Cancer. 2023 Dec; 186:107418 Epub 2023 Oct 31
    View PubMed
  17. Smith KER, Pritzl SL, Yu W, Bara I, Thanarajasingam G, Kaul MD, Williams KA, Dueck AC, Mansfield AS. The Timing, Trajectory, and Incidence of Immune-Related Adverse Events in NSCLC Treated With Atezolizumab. JTO Clin Res Rep. 2023 Dec; 4 (12):100611 Epub 2023 Nov 23
    View PubMed
  18. Desai A, Smith CJ, Ashara Y, Orme JJ, Zanwar S, Potter A, Hocum C, Moffett JN, Schwecke AJ, Manochakian R, Lou Y, Zhao Y, Ernani V, Savvides P, Molina J, Dimou A, Mansfield AS, Parikh K, Leventakos K. Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer. Clin Lung Cancer. 2023 Dec; 24 (8):689-695.e1 Epub 2023 Sept 17
    View PubMed
  19. Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourao Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N, PAPILLON Investigators. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30; 389 (22):2039-2051 Epub 2023 Oct 21
    View PubMed
  20. Gicobi JK, Mao Z, DeFranco G, Hirdler JB, Li Y, Vianzon VV, Dellacecca ER, Hsu MA, Barham W, Yan Y, Mansfield AS, Lin Y, Wu X, Hitosugi T, Owen D, Grams MP, Orme JJ, Lucien F, Zeng H, Park SS, Dong H. Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8(+) T cells via ME1 up-regulation. Sci Adv. 2023 Nov 17; 9 (46):eadi2414 Epub 2023 Nov 15
    View PubMed
  21. Sandoval L, Radhakrishnan Y, Vaughan LE, Potter A, Mansfield AS, Herrmann SM. Capmatinib-Associated Pseudoacute Kidney Injury in Nonsmall Cell Lung Cancer. Kidney Int Rep. 2023 Nov; 8 (11):2482-2485 Epub 2023 Aug 28
    View PubMed
  22. Wolf J, Souquet PJ, Goto K, Cortot A, Baik C, Heist R, Kim TM, Han JY, Neal JW, Mansfield AS, Gilloteau I, Nwana N, Waldron-Lynch M, Davis KL, Giovannini M, Awad MM. Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review. Clin Lung Cancer. 2023 Nov; 24 (7):641-650.e2 Epub 2023 Aug 13
    View PubMed
  23. Desai AP, Kosari F, Disselhorst M, Yin J, Agahi A, Peikert T, Udell J, Johnson SH, Smadbeck J, Murphy S, Karagouga G, McCune A, Schaefer-Klein J, Borad MJ, Cheville J, Vasmatzis G, Baas P, Mansfield A. Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy. J Immunother Cancer. 2023 Jun; 11 (6)
    View PubMed
  24. El Khoury LY, Lin WH, Smadbeck JB, Barrett MT, Sadeghian D, McCune AF, Karagouga G, Cheville JC, Harris FR, Kinsella LM, Feathers RW, Schafer Klein JL, Walther-Antonio MR, Johnson SH, Penheiter AR, Cucinella G, Schivardi G, Bhagwate A, Borad MJ, Mansfield AS, Murphy SJ, Mariani A, Vasmatzis G, Anastasiadis PZ, Weroha SJ, Larish AM. Epigenomics may begin to explain in vitro differential response to hypomethylating agents in MMR-D hypermethylated endometrial cancer. Epigenomics. 2023 Mar; 15 (5):283-292 Epub 2023 May 22
    View PubMed
  25. Desai A, Rakshit S, Bansal R, Ashara Y, Potter A, Manochakian R, Lou Y, Zhao Y, Ernani V, Savvides P, Schwecke A, Moffett N, Hocum C, Leventakos K, Adjei A, Marks R, Molina J, Mansfield AS, Chen ZM, Dimou A. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report. Cancer Treat Res Commun. 2023; 36:100743. Epub 2023 Jul 13.
    View PubMed
  26. Barham W, Hsu M, Liu X, Harrington SM, Hirdler JB, Gicobi JK, Zhu X, Zeng H, Pavelko KD, Yan Y, Mansfield AS, Dong H. A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration-Approved PD-1 and PD-L1 Inhibitors. Immunohorizons. 2023 Jan 1; 7 (1):125-139
    View PubMed
  27. Desai AP, Adashek JJ, Reuss JE, West HJ, Mansfield AS. Perioperative Immune Checkpoint Inhibition in Early-Stage Non-Small Cell Lung Cancer: A Review. JAMA Oncol. 2023 Jan 1; 9 (1):135-142
    View PubMed
  28. Wickland DP, Sherman ME, Radisky DC, Mansfield AS, Asmann YW. Response to Mitr and Pollack. J Natl Cancer Inst 2022 Dec 8; 114 (12):1729-1730
    View PubMed
  29. Dimou A, Lo YC, Merrell KW, Halling KC, Mansfield AS. Small Cell Transformation in a Patient With RET Fusion-Positive Lung Adenocarcinoma on Pralsetinib. JCO Precis Oncol. 2022 Dec; 6:e2200478
    View PubMed
  30. Buglioni A, Caffes PL, Hessler MG, Mansfield AS, Lo YC. Clinical Utility Validation of an Automated Ultrarapid Gene Fusion Assay for NSCLC. JTO Clin Res Rep. 2022 Dec; 3 (12):100434 Epub 2022 Nov 09
    View PubMed
  31. Dolezal JM, Srisuwananukorn A, Karpeyev D, Ramesh S, Kochanny S, Cody B, Mansfield AS, Rakshit S, Bansal R, Bois MC, Bungum AO, Schulte JJ, Vokes EE, Garassino MC, Husain AN, Pearson AT. Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology. Nat Commun. 2022 Nov 2; 13 (1):6572 Epub 2022 Nov 02
    View PubMed
  32. Perera ND, Mansfield AS. The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma. Curr Oncol Rep. 2022 Nov; 24 (11):1413-1423 Epub 2022 June 03
    View PubMed
  33. Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, Lee DH, Misch D, Garralda E, Kim DW, van der Wekken AJ, Gainor JF, Paz-Ares L, Liu SV, Kalemkerian GP, Houvras Y, Bowles DW, Mansfield AS, Lin JJ, Smoljanovic V, Rahman A, Kong S, Zalutskaya A, Louie-Gao M, Boral AL, Mazieres J. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022 Nov; 33 (11):1168-1178 Epub 2022 Aug 13
    View PubMed
  34. Reck M, Mok TSK, Mansfield A, De Boer R, Losonczy G, Sugawara S, Dziadziuszko R, Krzakowski M, Smolin A, Hochmair M, Garassino MC, de Castro Junior G, Bischoff H, Lam S, Cardona A, Morris S, Liu SV. Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide. J Thorac Oncol. 2022 Sep; 17 (9):1122-1129 Epub 2022 June 25
    View PubMed
  35. Wickland DP, Sherman ME, Radisky DC, Mansfield AS, Asmann YW. Lower Exome Sequencing Coverage of Ancestrally African Patients in The Cancer Genome Atlas. J Natl Cancer Inst. 2022 Aug 8; 114 (8):1192-1199
    View PubMed
  36. Uson Junior PLS, DeLeon TT, Bogenberger JM, Pai RK, Kosiorek HE, Yin J, Ahn DH, Sonbol MB, Bekaii-Saab T, Mansfield AS, Buetow K, Gores GJ, Smoot R, Vasmatzis G, Kipp BR, Mahipal A, Baker AT, Babiker H, Barro O, Dumbauld C, Zhou Y, Aslam FN, Barrett M, Jacobs B, Meurice N, Arora M, Petit J, Elliott N, Nagalo B, Salomao MA, Borad MJ. FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. Dig Dis Sci. 2022 Aug; 67(8):3797-3805. Epub 2021 Nov 13.
    View PubMed
  37. Carbone M, Pass HI, Ak G, Alexander HR Jr, Baas P, Baumann F, Blakely AM, Bueno R, Bzura A, Cardillo G, Churpek JE, Dianzani I, De Rienzo A, Emi M, Emri S, Felley-Bosco E, Fennell DA, Flores RM, Grosso F, Hayward NK, Hesdorffer M, Hoang CD, Johansson PA, Kindler HL, Kittaneh M, Krausz T, Mansfield A, Metintas M, Minaai M, Mutti L, Nielsen M, O'Byrne K, Opitz I, Pastorino S, Pentimalli F, de Perrot M, Pritchard A, Ripley RT, Robinson B, Rusch V, Taioli E, Takinishi Y, Tanji M, Tsao AS, Tuncer AM, Walpole S, Wolf A, Yang H, Yoshikawa Y, Zolondick A, Schrump DS, Hassan R. Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. J Thorac Oncol. 2022 Jul; 17 (7):873-889 Epub 2022 Apr 21
    View PubMed
  38. Uson Junior PLS, Majeed U, Yin J, Botrus G, Sonbol MB, Ahn DH, Starr JS, Jones JC, Babiker H, Inabinett SR, Wylie N, Boyle AWR, Bekaii-Saab TS, Gores GJ, Smoot R, Barrett M, Nagalo B, Meurice N, Elliott N, Petit J, Zhou Y, Arora M, Dumbauld C, Barro O, Baker A, Bogenberger J, Buetow K, Mansfield A, Mody K, Borad MJ. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. JCO Precis Oncol. 2022 Jun; 6 (1):e2100274
    View PubMed
  39. Kommalapati A, Mansfield AS. Trials, tribunals, and opportunities for lung cancer KRASG12C brain metastases. Clin Cancer Res. 2022 May 24 [Epub ahead of print]
    View PubMed
  40. Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, Nowak AK, Fujimoto N, Tsao AS, Mansfield AS, Popat S, Zhang X, Hu N, Balli D, Spires T, Zalcman G. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022 May; 33 (5):488-499 Epub 2022 Feb 03
    View PubMed
  41. Scherpereel A, Antonia S, Bautista Y, Grossi F, Kowalski D, Zalcman G, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Sun X, Lawrance R, Zhang X, Daumont MJ, Bennett B, McKenna M, Baas P. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Lung Cancer. 2022 May; 167:8-16 Epub 2022 Mar 21
    View PubMed
  42. Mansfield AS, Brown RJ, Sammon C, Daumont MJ, McKenna M, Sanzari JK, Forde PM. The Predictive and Prognostic Nature of Programmed Death-Ligand 1 in Malignant Pleural Mesothelioma: A Systematic Literature Review. JTO Clin Res Rep. 2022 May; 3 (5):100315 Epub 2022 Mar 22
    View PubMed
  43. Mansfield AS, Wei Z, Mehra R, Shaw AT, Lieu CH, Forde PM, Drilon AE, Mitchell EP, Wright JJ, Takebe N, Sharon E, Hovelson D, Tomlins S, Zeng J, Poorman K, Malik N, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. NPJ Precis Oncol. 2022 Mar 1; 6 (1):13 Epub 2022 Mar 01
    View PubMed
  44. Naing A, Powderly JD, Nemunaitis JJ, Luke JJ, Mansfield AS, Messersmith WA, Sahebjam S, LoRusso PM, Garrido-Laguna I, Leopold L, Geschwindt R, Ding K, Smith M, Berlin JD. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. J Immunother Cancer. 2022 Mar; 10 (3)
    View PubMed
  45. Kosari F, Disselhorst M, Yin J, Peikert T, Udell J, Johnson S, Smadbeck J, Murphy S, McCune A, Karagouga G, Desai A, Schaefer-Klein J, Borad MJ, Cheville J, Vasmatzis G, Baas P, Mansfield AS. Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors. J Thorac Oncol. 2022 Mar; 17 (3):446-454 Epub 2021 Nov 17
    View PubMed
  46. Tsao AS, Pass HI, Rimner A, Mansfield AS. New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options. J Clin Oncol. 2022 Feb 20; 40 (6):681-692 Epub 2022 Jan 05
    View PubMed
  47. Wen T, Barham W, Li Y, Zhang H, Gicobi JK, Hirdler JB, Liu X, Ham H, Peterson Martinez KE, Lucien F, Lavoie RR, Li H, Correia C, Monie DD, An Z, Harrington SM, Wu X, Guo R, Dronca RS, Mansfield AS, Yan Y, Markovic SN, Park SS, Sun J, Qin H, Liu MC, Vasmatzis G, Billadeau DD, Dong H. NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy. Cancer Immunol Res. 2022 Feb; 10 (2):162-181 Epub 2021 Dec 15
    View PubMed
  48. Ahn DH, Uson Junior PLS, Masci P, Kosiorek H, Halfdanarson TR, Mody K, Babiker H, DeLeon T, Sonbol MB, Gores G, Smoot R, Bekaii-Saab T, Mahipal A, Mansfield A, Tran NH, Hubbard JM, Borad MJ. A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. Invest New Drugs. 2022 Feb; 40 (1):134-141 Epub 2021 Aug 31
    View PubMed
  49. Kanakkanthara A, Hou X, Ekstrom TL, Zanfagnin V, Huehls AM, Kelly RL, Ding H, Larson MC, Vasmatzis G, Oberg AL, Kaufmann SH, Mansfield AS, Weroha SJ, Karnitz LM. Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma. Cancer Res. 2022 Jan 15; 82 (2):307-319 Epub 2021 Nov 22
    View PubMed
  50. Roden AC, Rakshit S, Johnson GB, Jenkins SM, Mansfield AS. Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors. Front Oncol. 2022; 12:823667 Epub 2022 Feb 07
    View PubMed
  51. Arora M, Bogenberger JM, Abdelrahman AM, Yonkus J, Alva-Ruiz R, Leiting JL, Chen X, Serrano Uson Junior PL, Dumbauld CR, Baker AT, Gamb SI, Egan JB, Zhou Y, Nagalo BM, Meurice N, Eskelinen EL, Salomao MA, Kosiorek HE, Braggio E, Barrett MT, Buetow KH, Sonbol MB, Mansfield AS, Roberts LR, Bekaii-Saab TS, Ahn DH, Truty MJ, Borad MJ. Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers. Hepatology. 2022 Jan; 75 (1):43-58 Epub 2021 Dec 12
    View PubMed
  52. Yang F, Wang Y, Tang L, Mansfield AS, Adjei AA, Leventakos K, Duma N, Wei J, Wang L, Liu B, Molina JR. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis. Front Oncol. 2022; 12:955440 Epub 2022 Aug 16
    View PubMed
  53. Pal K, Hussain T, Xie H, Li S, Yang P, Mansfield A, Lou Y, Chowdhury S, Mukhopadhyay D. Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma. Front Oncol. 2022; 12:959500 Epub 2022 Aug 22
    View PubMed
  54. Vrana JA, Boland JM, Terra SBSP, Xie H, Jenkins SM, Mansfield AS, Molina JR, Cassivi SD, Roden AC. SATB2 Is Expressed in a Subset of Pulmonary and Thymic Neuroendocrine Tumors. Am J Clin Pathol. 2021 Oct 13; 156(5):853-865.
    View PubMed
  55. Janku F, LoRusso P, Mansfield AS, Nanda R, Spira A, Wang T, Melhem-Bertrandt A, Sugg J, Ball HA. First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer. Invest New Drugs. 2021 Oct; 39 (5):1348-1356 Epub 2021 Apr 08
    View PubMed
  56. Hazim A, Majithia N, Murphy SJ, Wigle D, Aubry MC, Mansfield AS. Heterogeneity of PD-L1 expression between invasive and lepidic components of lung adenocarcinomas. Cancer Immunol Immunother. 2021 Sep; 70 (9):2651-2656 Epub 2021 Feb 18
    View PubMed
  57. Mansfield AS, Hong DS, Hann CL, Farago AF, Beltran H, Waqar SN, Hendifar AE, Anthony LB, Taylor MH, Bryce AH, Tagawa ST, Lewis K, Niu J, Chung CH, Cleary JM, Rossi M, Ludwig C, Valenzuela R, Luo Y, Aggarwal R. A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol. 2021 Aug 5; 5 (1):74 Epub 2021 Aug 05
    View PubMed
  58. Mansfield AS, Herbst RS, de Castro G Jr, Hui R, Peled N, Kim DW, Novello S, Satouchi M, Wu YL, Garon EB, Reck M, Robinson AG, Samkari A, Piperdi B, Ebiana V, Lin J, Mok TSK. Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. JTO Clin Res Rep. 2021 Aug; 2 (8):100205 Epub 2021 July 01
    View PubMed
  59. Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021 Aug; 9 (8):491-501 Epub 2021 June 09
    View PubMed
  60. Shafique MR, Fisher TL, Evans EE, Leonard JE, Pastore DRE, Mallow CL, Smith E, Mishra V, Schroder A, Chin KM, Beck JT, Baumgart MA, Govindan R, Gabrail NY, Spira AI, Seetharamu N, Lou Y, Mansfield AS, Sanborn RE, Goldman JW, Zauderer M. A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2021 Jul 1; 27 (13):3630-3640 Epub 2021 Apr 05
    View PubMed
  61. Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021 Jul; 22 (7):959-969 Epub 2021 June 09
    View PubMed
  62. Breen WG, Jeans EB, Gergelis KR, Garces YI, Park SS, Merrell KW, Peikert TD, Mansfield AS, Wigle DA, Harmsen WS, Ellerbusch DC, Olivier KR, John Lucido J, Owen D. Ablative radiotherapy for ultracentral lung cancers: Dosimetric, geometric, and volumetric predictors of outcomes and toxicity. Radiother Oncol. 2021 May; 158:246-252 Epub 2021 Mar 10
    View PubMed
  63. Wong W, Wu N, Gupta R, Mansfield AS. Utilization Trends and Factors Associated With ROS1 Testing Among Patients With Advanced Non-small-cell Lung Cancer in US Community Practices. Clin Lung Cancer. 2021 May; 22 (3):e470-e480 Epub 2020 June 29
    View PubMed
  64. Asmann YW, Parikh K, Bergsagel PL, Dong H, Adjei AA, Borad MJ, Mansfield AS. Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups. NPJ Precis Oncol. 2021 Mar 19; 5 (1):22
    View PubMed
  65. Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, Garassino MC, De Castro Carpeno J, Califano R, Nishio M, Orlandi F, Alatorre-Alexander J, Leal T, Cheng Y, Lee JS, Lam S, McCleland M, Deng Y, Phan S, Horn L. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021 Feb 20; 39 (6):619-630 Epub 2021 Jan 13
    View PubMed
  66. Busacca S, O'Regan L, Singh A, Sharkey AJ, Dawson AG, Dzialo J, Parsons A, Kumar N, Schunselaar LM, Guppy N, Nakas A, Sheaff M, Mansfield AS, Janes SM, Baas P, Fry AM, Fennell DA. BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma. Mol Cancer Ther. 2021 Feb; 20 (2):379-388 Epub 2020 Nov 06
    View PubMed
  67. Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodriguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021 Jan 30; 397 (10272):375-386 Epub 2021 Jan 21
    View PubMed
  68. Failing JJ, Aubry MC, Mansfield AS. Human leukocyte antigen expression in paired primary lung tumors and brain metastases in non-small cell lung cancer. Cancer Immunol Immunother. 2021 Jan; 70 (1):215-219 Epub 2020 July 21
    View PubMed
  69. Peng X, Long X, Liu L, Zeng L, Yang H, Jiang W, Liao D, Li K, Wang J, Lizaso A, Mao X, Xu Q, Mansfield AS, Yang N, Zhang Y. Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer. Eur J Cancer. 2020 Dec; 141:199-208 Epub 2020 Nov 07
    View PubMed
  70. Murphy SJ, Harris FR, Smadbeck JB, Serla V, Karagouga G, Johnson SH, Kosari F, Pierson KE, Bungum AO, Edell ES, Mansfield AS, Wigle DA, Kipp BR, Vasmatzis G, Aubry MC. Optimizing clinical cytology touch preparations for next generation sequencing. Genomics. 2020 Nov; 112(6):5313-5323. Epub 2020 Nov 02.
    View PubMed
  71. Mansfield AS. Maintaining Equipoise With Maintenance Therapy in Mesothelioma. Clin Lung Cancer 2020 Nov; 21 (6):482-484 Epub 2020 July 18
    View PubMed
  72. Shah KK, Neff JL, Erickson LA, Jackson RA, Jenkins SM, Mansfield AS, Moser JC, Harris AL, Copland JA, Halling KC, Flotte TJ. Correlation of novel ALK(ATI) with ALK immunohistochemistry and clinical outcomes in metastatic melanoma. Histopathology. 2020 Oct; 77 (4):601-610 Epub 2020 Sept 15
    View PubMed
  73. Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS, GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3; 383 (10):944-957
    View PubMed
  74. Xie H, Kaye FJ, Isse K, Sun Y, Ramoth J, French DM, Flotte TJ, Luo Y, Saunders LR, Mansfield AS. Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma. Oncologist. 2020 Sep; 25 (9):810-817 Epub 2020 May 14
    View PubMed
  75. Cathcart-Rake EJ, Sangaralingham LR, Henk HJ, Shah ND, Riaz IB, Mansfield AS. A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer. Clin Lung Cancer. 2020 Sep; 21 (5):421-427.e2 Epub 2020 Apr 13
    View PubMed
  76. Orme JJ, Enninga EAL, Lucien-Matteoni F, Dale H, Burgstaler E, Harrington SM, Ball MK, Mansfield AS, Park SS, Block MS, Markovic SN, Yan Y, Dong H, Dronca RS, Winters JL. Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles. J Immunother Cancer. 2020 Aug; 8 (2)
    View PubMed
  77. Chae YK, Hong F, Vaklavas C, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. J Clin Oncol. 2020 Jul 20; 38 (21):2407-2417 Epub 2020 May 28
    View PubMed
  78. Yu Y, Ruddy K, Mansfield A, Zong N, Wen A, Tsuji S, Huang M, Liu H, Shah N, Jiang G. Detecting and Filtering Immune-Related Adverse Events Signal Based on Text Mining and Observational Health Data Sciences and Informatics Common Data Model: Framework Development Study. JMIR Med Inform. 2020 Jun 12; 8 (6):e17353 Epub 2020 June 12
    View PubMed
  79. Zhang Y, Zeng L, Zhou C, Li Y, Wu L, Xia C, Jiang W, Hu Y, Liao D, Xiao L, Liu L, Yang H, Xiong Y, Guan R, Lizaso A, Mansfield AS, Yang N. Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC. J Thorac Oncol. 2020 Jun; 15 (6):1027-1036 Epub 2020 Feb 27
    View PubMed
  80. Sheinson D, Wong WB, Wu N, Mansfield AS. Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer. Lung Cancer. 2020 May; 143:86-92 Epub 2020 Mar 07
    View PubMed
  81. Duma N, Idossa DW, Durani U, Frank RD, Paludo J, Westin G, Lou Y, Mansfield AS, Adjei AA, Go RS, Ailawadhi S. Influence of Sociodemographic Factors on Treatment Decisions in Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 May; 21 (3):e115-e129 Epub 2019 Aug 30
    View PubMed
  82. Chabon JJ, Hamilton EG, Kurtz DM, Esfahani MS, Moding EJ, Stehr H, Schroers-Martin J, Nabet BY, Chen B, Chaudhuri AA, Liu CL, Hui AB, Jin MC, Azad TD, Almanza D, Jeon YJ, Nesselbush MC, Co Ting Keh L, Bonilla RF, Yoo CH, Ko RB, Chen EL, Merriott DJ, Massion PP, Mansfield AS, Jen J, Ren HZ, Lin SH, Costantino CL, Burr R, Tibshirani R, Gambhir SS, Berry GJ, Jensen KC, West RB, Neal JW, Wakelee HA, Loo BW Jr, Kunder CA, Leung AN, Lui NS, Berry MF, Shrager JB, Nair VS, Haber DA, Sequist LV, Alizadeh AA, Diehn M. Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020 Apr; 580(7802):245-251. Epub 2020 Mar 25.
    View PubMed
  83. Patel SR, Brown SN, Kubusek JE, Mansfield AS, Duma N. Osimertinib-Induced Cardiomyopathy. JACC Case Rep. 2020 Apr; 2 (4):641-645 Epub 2020 Apr 01
    View PubMed
  84. Breen WG, Garces YI, Olivier KR, Park SS, Merrell KW, Nichols FC, Peikert TD, Molina JR, Mansfield AS, Roden AC, Blackmon SH, Wigle DA. Surgery for Mesothelioma After Radiation Therapy (SMART); A Single Institution Experience. Front Oncol. 2020; 10:392 Epub 2020 Mar 24
    View PubMed
  85. Zeng L, Xiao L, Jiang W, Yang H, Hu D, Xia C, Li Y, Zhou C, Xiong Y, Liu L, Liao D, Guan R, Li K, Wang J, Zhang Y, Yang N, Mansfield AS. Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population. Lung Cancer. 2020 Mar; 141:82-88 Epub 2020 Jan 13
    View PubMed
  86. Parikh K, Huether R, White K, Hoskinson D, Beaubier N, Dong H, Adjei AA, Mansfield AS. Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens. JAMA Netw Open. 2020 Feb 5; 3 (2):e200202 Epub 2020 Feb 05
    View PubMed
  87. Mansfield AS, Peikert T, Vasmatzis G. Chromosomal rearrangements and their neoantigenic potential in mesothelioma. Transl Lung Cancer Res. 2020 Feb; 9 (Suppl 1):S92-S99
    View PubMed
  88. Mansfield AS, Kazarnowicz A, Karaseva N, Sanchez A, De Boer R, Andric Z, Reck M, Atagi S, Lee JS, Garassino M, Liu SV, Horn L, Wen X, Quach C, Yu W, Kabbinavar F, Lam S, Morris S, Califano R. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. Ann Oncol. 2020 Feb; 31 (2):310-317 Epub 2019 Dec 09
    View PubMed
  89. Orme JJ, Jazieh KA, Xie T, Harrington S, Liu X, Ball M, Madden B, Charlesworth MC, Azam TU, Lucien F, Wootla B, Li Y, Villasboas JC, Mansfield AS, Dronca RS, Dong H. ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. Oncoimmunology. 2020; 9 (1):1744980 Epub 2020 Apr 14
    View PubMed
  90. Ren Y, Cherukuri Y, Wickland DP, Sarangi V, Tian S, Carter JM, Mansfield AS, Block MS, Sherman ME, Knutson KL, Lin Y, Asmann YW. HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. Oncoimmunology. 2020; 9 (1):1744947 Epub 2020 Apr 01
    View PubMed
  91. Duma N, Abdel-Ghani A, Yadav S, Hoversten KP, Reed CT, Sitek AN, Enninga EAL, Paludo J, Aguilera JV, Leventakos K, Lou Y, Kottschade LA, Dong H, Mansfield AS, Manochakian R, Adjei AA, Dronca RS. Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal? Oncologist. 2019 Nov; 24 (11):e1148-e1155 Epub 2019 Apr 29
    View PubMed
  92. Tsao MS, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, Liu G, Malik S, Nowak A, Peikert T, Salgia R, Szlosarek P, Taioli E, Yang H, Tsao A, Mansfield AS. Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. J Thorac Oncol. 2019 Oct; 14 (10):1704-1717 Epub 2019 June 28
    View PubMed
  93. Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG 3rd, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB 2nd, de Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH Jr, Hesdorffer M, Hirsch FR, Pass HI, Yorke E, Rosenzweig K, Burt B, Fennell DA, Lindwasser W, Malik S, Peikert T, Mansfield AS, Salgia R, Yang H, Rusch VW, Nowak AK. Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019 Oct; 14 (10):1718-1731 Epub 2019 Aug 27
    View PubMed
  94. Mansfield AS, Zauderer MG. Nivo-lution in Mesothelioma. Clin Cancer Res 2019 Sep 15; 25 (18):5438-5440 Epub 2019 July 17
    View PubMed
  95. Murphy SJ, Harris FR, Kosari F, Barreto Siqueira Parrilha Terra S, Nasir A, Johnson SH, Serla V, Smadbeck JB, Halling GC, Karagouga G, Sukov WR, Leventakos K, Yang P, Peikert T, Mansfield AS, Wigle DA, Yi ES, Kipp BR, Vasmatzis G, Aubry MC. Using Genomics to Differentiate Multiple Primaries From Metastatic Lung Cancer. J Thorac Oncol. 2019 Sep; 14 (9):1567-1582 Epub 2019 May 16
    View PubMed
  96. Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019 Sep; 69 (5):402-429 Epub 2019 July 08
    View PubMed
  97. Xie H, Boland JM, Maleszewski JJ, Aubry MC, Yi ES, Jenkins SM, Koepplin JW, Terra SBSP, Mansfield AS, Roden AC. Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors. Lung Cancer. 2019 Sep; 135:73-79 Epub 2019 July 17
    View PubMed
  98. Mody K, Mansfield AS, Vemireddy L, Nygren P, Gulbo J, Borad M. A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors. Invest New Drugs. 2019 Aug; 37 (4):684-692 Epub 2018 Nov 21
    View PubMed
  99. Wang S, Zimmermann S, Parikh K, Mansfield AS, Adjei AA. Current Diagnosis and Management of Small-Cell Lung Cancer. Mayo Clin Proc. 2019 Aug; 94 (8):1599-1622
    View PubMed
  100. Muppa P, Parrilha Terra SBS, Sharma A, Mansfield AS, Aubry MC, Bhinge K, Asiedu MK, de Andrade M, Janaki N, Murphy SJ, Nasir A, Van Keulen V, Vasmatzis G, Wigle DA, Yang P, Yi ES, Peikert T, Kosari F. Immune Cell Infiltration May Be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer. J Thorac Oncol. 2019 Jul; 14 (7):1286-1295 Epub 2019 May 09
    View PubMed
  101. Stewart M, Norden AD, Dreyer N, Henk HJ, Abernethy AP, Chrischilles E, Kushi L, Mansfield AS, Khozin S, Sharon E, Arunajadai S, Carnahan R, Christian JB, Miksad RA, Sakoda LC, Torres AZ, Valice E, Allen J. An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer. JCO Clin Cancer Inform. 2019 Jul; 3:1-15
    View PubMed
  102. Boyum JH, Atwell TD, Wall DJ, Mansfield AS, Kerr SE, Gunderson TM, Rumilla KM, Weisbrod AJ, Kurup AN. Incidence of major hemorrhage after aggressive image-guided liver mass biopsy in the era of individualized medicine. Abdom Radiol (NY). 2019 Jun; 44 (6):2067-2073
    View PubMed
  103. Sebastian M, Barlesi F, Califano R, Mansfield AS, Blackhall FH, Flahavan EM, Davies J, Arnold P, Morris S, Reck M. Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice. Ann Oncol. 2019 Apr; 30 Suppl 2:ii24
    View PubMed
  104. Leventakos K, Helgeson J, Mansfield AS, Deering E, Schwecke A, Adjei A, Molina J, Hocum C, Halfdanarson T, Marks R, Parikh K, Pomerleau K, Coverdill S, Rammage M, Haddad T. Implementation of artificial intelligence (AI) for lung cancer clinical trial matching in a tertiary cancer center. Ann Oncol. 2019 Apr; 30 Suppl 2:ii74
    View PubMed
  105. Wu X, Li Y, Liu X, Chen C, Harrington SM, Cao S, Xie T, Pham T, Mansfield AS, Yan Y, Kwon ED, Wang L, Ling K, Dong H. Corrigendum to "Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy" [Heliyon 4 (12) (December 2018) e01039]. Heliyon. 2019 Mar; 5 (3):e01309 Epub 2019 Mar 18
    View PubMed
  106. Ren H, Hou X, Eiken PW, Zhang J, Pierson KE, Nair AA, Davila JI, Kovarikova H, Jang JS, Johnson SH, Molina JR, Marks RS, Yang P, Yi JE, Mansfield AS, Jen J. Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion. Clin Lung Cancer. 2019 Mar; 20(2):e142-e147. Epub 2018 Nov 20.
    View PubMed
  107. Mansfield AS, Jen J. Predicting Treatment Response Based on RNA Expression in Large Datasets. Clin Cancer Res 2019 Mar 1; 25 (5):1443-1445 Epub 2018 Nov 16
    View PubMed
  108. Mansfield AS, Peikert T, Smadbeck JB, Udell JBM, Garcia-Rivera E, Elsbernd L, Erskine CL, Van Keulen VP, Kosari F, Murphy SJ, Ren H, Serla VV, Schaefer Klein JL, Karagouga G, Harris FR, Sosa C, Johnson SH, Nevala W, Markovic SN, Bungum AO, Edell ES, Dong H, Cheville JC, Aubry MC, Jen J, Vasmatzis G. Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma. J Thorac Oncol. 2019 Feb; 14 (2):276-287 Epub 2018 Oct 10
    View PubMed
  109. Yan Y, Leontovich AA, Gerdes MJ, Desai K, Dong J, Sood A, Santamaria-Pang A, Mansfield AS, Chadwick C, Zhang R, Nevala WK, Flotte TJ, Ginty F, Markovic SN. Understanding heterogeneous tumor microenvironment in metastatic melanoma. PLoS One. 2019; 14 (6):e0216485 Epub 2019 June 05
    View PubMed
  110. Duma N, Kothadia SM, Azam TU, Yadav S, Paludo J, Vera Aguilera J, Gonzalez Velez M, Halfdanarson TR, Molina JR, Hubbard JM, Go RS, Mansfield AS, Adjei AA. Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials. Oncologist. 2019 Jan; 24 (1):96-102 Epub 2018 Nov 09
    View PubMed
  111. Evans JD, Morris LK, Zhang H, Cao S, Liu X, Mara KC, Stish BJ, Davis BJ, Mansfield AS, Dronca RS, Iott MJ, Kwon ED, Foote RL, Olivier KR, Dong H, Park SS. Prospective Immunophenotyping of CD8(+) T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT. Int J Radiat Oncol Biol Phys. 2019 Jan 1; 103 (1):229-240 Epub 2018 Sept 08
    View PubMed
  112. Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV, IMpower133 Study Group. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018 Dec 6; 379 (23):2220-2229 Epub 2018 Sept 25
    View PubMed
  113. Wu X, Li Y, Liu X, Chen C, Harrington SM, Cao S, Xie T, Pham T, Orzechowski A, Mansfield AS, Yan Y, Kwon ED, Wang L, Ling K, Dong H. Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy. Heliyon. 2018 Dec; 4 (12):e01039 Epub 2018 Dec 18
    View PubMed
  114. Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2018 Nov; 13 (11):1655-1667 Epub 2018 Sept 25
    View PubMed
  115. Reisenauer JS, Mneimneh W, Jenkins S, Mansfield AS, Aubry MC, Fritchie KJ, Allen MS, Blackmon SH, Cassivi SD, Nichols FC, Wigle DA, Shen KR, Boland JM. Comparison of Risk Stratification Models to Predict Recurrence and Survival in Pleuropulmonary Solitary Fibrous Tumor. J Thorac Oncol. 2018 Sep; 13 (9):1349-1362 Epub 2018 June 20
    View PubMed
  116. Mansfield AS, Peikert T, Vogelzang NJ, Symanowski JT. Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma. Mayo Clin Proc. 2018 Aug; 93 (8):1026-1033 Epub 2018 May 24
    View PubMed
  117. Xie D, Allen MS, Marks R, Jiang G, Sun Z, Nichols F, Zhang M, Chen C, Aubry MC, Jatoi A, Garces YI, Mansfield A, Wigle D, Molina J, Deschamps C, Yang P. Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers. Eur J Cardiothorac Surg. 2018 Jun 1; 53 (6):1214-1222
    View PubMed
  118. Mansfield AS, Park BH, Mullane MP. Identification, Prioritization, and Treatment of Mutations Identified by Next-Generation Sequencing. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:873-880
    View PubMed
  119. McCambridge AJ, Napolitano A, Mansfield AS, Fennell DA, Sekido Y, Nowak AK, Reungwetwattana T, Mao W, Pass HI, Carbone M, Yang H, Peikert T. Progress in the Management of Malignant Pleural Mesothelioma in 2017. J Thorac Oncol. 2018 May; 13 (5):606-623 Epub 2018 Mar 08
    View PubMed
  120. Yan Y, Cao S, Liu X, Harrington SM, Bindeman WE, Adjei AA, Jang JS, Jen J, Li Y, Chanana P, Mansfield AS, Park SS, Markovic SN, Dronca RS, Dong H. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight. 2018 Apr 19; 3 (8)
    View PubMed
  121. Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, Douville C, Javed AA, Wong F, Mattox A, Hruban RH, Wolfgang CL, Goggins MG, Dal Molin M, Wang TL, Roden R, Klein AP, Ptak J, Dobbyn L, Schaefer J, Silliman N, Popoli M, Vogelstein JT, Browne JD, Schoen RE, Brand RE, Tie J, Gibbs P, Wong HL, Mansfield AS, Jen J, Hanash SM, Falconi M, Allen PJ, Zhou S, Bettegowda C, Diaz LA Jr, Tomasetti C, Kinzler KW, Vogelstein B, Lennon AM, Papadopoulos N. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018 Feb 23; 359 (6378):926-930 Epub 2018 Jan 18
    View PubMed
  122. Mansfield AS, Ren H, Sutor S, Sarangi V, Nair A, Davila J, Elsbernd LR, Udell JB, Dronca RS, Park S, Markovic SN, Sun Z, Halling KC, Nevala WK, Aubry MC, Dong H, Jen J. Contraction of T cell richness in lung cancer brain metastases. Sci Rep. 2018 Feb 1; 8 (1):2171 Epub 2018 Feb 01
    View PubMed
  123. Duma N, Vera Aguilera J, Paludo J, Haddox CL, Gonzalez Velez M, Wang Y, Leventakos K, Hubbard JM, Mansfield AS, Go RS, Adjei AA. Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years. J Oncol Pract. 2018 Jan; 14 (1):e1-e10 Epub 2017 Nov 03
    View PubMed
  124. Alam SK, Astone M, Liu P, Hall SR, Coyle AM, Dankert EN, Hoffman DK, Zhang W, Kuang R, Roden AC, Mansfield AS, Hoeppner LH. DARPP-32 and t-DARPP promote non-small cell lung cancer growth through regulation of IKKa-dependent cell migration. Commun Biol. 2018; 1:43. Epub 2018 May 03.
    View PubMed
  125. Arnett AL, Packard AT, Mara K, Mansfield AS, Wigle DA, Haddock MG, Park SS, Olivier KR, Garces YI, Merrell KW. FDG-PET parameters as predictors of pathologic response and nodal clearance in patients with stage III non-small cell lung cancer receiving neoadjuvant chemoradiation and surgery. Pract Radiat Oncol. 2017 Nov - Dec; 7 (6):e531-e541 Epub 2017 Apr 19
    View PubMed
  126. Enninga EAL, Moser JC, Weaver AL, Markovic SN, Brewer JD, Leontovich AA, Hieken TJ, Shuster L, Kottschade LA, Olariu A, Mansfield AS, Dronca RS. Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992-2011. Cancer Med. 2017 Oct; 6 (10):2203-2212 Epub 2017 Sept 06
    View PubMed
  127. Dose AM, Hubbard JM, Mansfield AS, McCabe PJ, Krecke CA, Sloan JA. Feasibility and Acceptability of a Dignity Therapy/Life Plan Intervention for Patients With Advanced Cancer. Oncol Nurs Forum. 2017 Sep 1; 44 (5):E194-E202
    View PubMed
  128. Leventakos K, Peikert T, Midthun DE, Molina JR, Blackmon S, Nichols FC, Garces YI, Hallemeier CL, Murphy SJ, Vasmatzis G, Kratz SL, Holland WP, Thomas CF, Mullon JJ, Shen KR, Cassivi SD, Marks RS, Aubry MC, Adjei AA, Yang P, Allen MS, Edell ES, Wigle D, Mansfield AS. Management of Multifocal Lung Cancer: Results of a Survey. J Thorac Oncol. 2017 Sep; 12 (9):1398-1402 Epub 2017 June 03
    View PubMed
  129. Schenk E, Boland J, Mansfield A, Aubry MC, Dietz A. Local and systemic immunity predict survival in patients with pulmonary sarcomatoid carcinoma. Med Oncol. 2017 Aug; 34 (8):140 Epub 2017 July 15
    View PubMed
  130. Chung V, Mansfield AS, Braiteh F, Richards D, Durivage H, Ungerleider RS, Johnson F, Kovach JS. Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial. Clin Cancer Res. 2017 Jul 1; 23 (13):3277-3284 Epub 2016 Dec 30
    View PubMed
  131. Kayastha GK, Ranjitkar N, Gurung R, Kc RK, Karki S, Shrestha R, Thapa RK, Rajbhandari P, Poudyal B, Acharya P, Roberts DJ, Hayes B, Zimmerman M, Basnyat B, Mansfield A. Treating Philadelphia chromosome/BCR-ABL1 positive patients with Glivec (Imatinib mesylate): 10 years' experience at Patan Hospital, Nepal. Br J Haematol. 2017 Jun; 177 (6):991-999 Epub 2017 Mar 29
    View PubMed
  132. Fuentes HE, Oramas DM, Paz LH, Casanegra AI, Mansfield AS, Tafur AJ. Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer. Thromb Res. 2017 Jun; 154:28-34 Epub 2017 Apr 01
    View PubMed
  133. Bhinge K, Yang L, Terra S, Nasir A, Muppa P, Aubry MC, Yi J, Janaki N, Kovtun IV, Murphy SJ, Halling G, Rahi H, Mansfield A, de Andrade M, Yang P, Vasmatzis G, Peikert T, Kosari F. EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression. Oncotarget. 2017 Apr 18; 8 (16):27155-27165
    View PubMed
  134. Bryce AH, Egan JB, Borad MJ, Stewart AK, Nowakowski GS, Chanan-Khan A, Patnaik MM, Ansell SM, Banck MS, Robinson SI, Mansfield AS, Klee EW, Oliver GR, McCormick JB, Huneke NE, Tagtow CM, Jenkins RB, Rumilla KM, Kerr SE, Kocher JA, Beck SA, Fernandez-Zapico ME, Farrugia G, Lazaridis KN, McWilliams RR. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. Oncotarget. 2017 Apr 18; 8 (16):27145-27154
    View PubMed
  135. Jatoi A, Grudem ME, Dockter TJ, Block MS, Villasboas JC, Tan A, Deering E, Kasi PM, Mansfield AS, Botero JP, Okuno SH, Smith DR, Fields AP. A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome. Support Care Cancer. 2017 Mar; 25(3):833-838. Epub 2016 Nov 12.
    View PubMed
  136. Mansfield AS, Tafur AJ. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer: reply. J Thromb Haemost 2017 Mar; 15 (3):591-592 Epub 2017 Feb 03
    View PubMed
  137. Iftikhar O, Silva-Palacios F, Cherry M, Mansfield A, Stoner J, Tafur A. Predictors of active cancer thromboembolic outcomes: role of body composition. Int Angiol 2017 Feb; 36 (1):88-89
    View PubMed
  138. Egan JB, Marks DL, Hogenson TL, Vrabel AM, Sigafoos AN, Tolosa EJ, Carr RM, Safgren SL, Hesles EE, Almada LL, Romecin-Duran PA, Iguchi E, Ala'Aldeen A, Kocher JA, Oliver GR, Prodduturi N, Mead DW, Hossain A, Huneke NE, Tagtow CM, Ailawadhi S, Ansell SM, Banck MS, Bryce AH, Carballido EM, Chanan-Khan AA, Curtis KK, Resnik E, Gawryletz CD, Go RS, Halfdanarson TR, Ho TH, Joseph RW, Kapoor P, Mansfield AS, Meurice N, Nageswara Rao AA, Nowakowski GS, Pardanani A, Parikh SA, Cheville JC, Feldman AL, Ramanathan RK, Robinson SI, Tibes R, Finnes HD, McCormick JB, McWilliams RR, Jatoi A, Patnaik MM, Silva AC, Wieben ED, McAllister TM, Rumilla KM, Kerr SE, Lazaridis KN, Farrugia G, Stewart AK, Clark KJ, Kennedy EJ, Klee EW, Borad MJ, Fernandez-Zapico ME. Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma. JCO Precis Oncol. 2017; 2017 Epub 2017 Aug 01
    View PubMed
  139. Breen WG, Merrell KW, Mansfield AS, Wigle DA, Garces YI, Park SS, Olivier KR, Hallemeier CL. Predictors of relapse and evaluation of the role of postoperative radiation therapy in a modern series of patients with surgically resected stage III (N2) non-small cell lung cancer. Adv Radiat Oncol. 2017 Jan-Mar; 2 (1):12-18 Epub 2016 Dec 21
    View PubMed
  140. Terra SBSP, Mansfield AS, Dong H, Peikert T, Roden AC. Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma. Oncoimmunology. 2017; 6 (11):e1356146 Epub 2017 July 27
    View PubMed
  141. Dronca RS, Mansfield AS, Park SS, Dong H. BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma. Immunotherapy 2016 Dec; 8 (12):1351-1353 Epub 2016 Oct 27
    View PubMed
  142. Mansfield AS, Rudek MA, Vulih D, Smith GL, Harris PJ, Ivy SP, NCI Organ Dysfunction Working Group. The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects. Clin Cancer Res. 2016 Nov 15; 22 (22):5472-5479 Epub 2016 May 17
    View PubMed
  143. Liu X, Wu X, Cao S, Harrington SM, Yin P, Mansfield AS, Dong H. B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8(+) T cells. Sci Rep. 2016 Nov 8; 6:36722 Epub 2016 Nov 08
    View PubMed
  144. Mansfield AS, Murphy SJ, Harris FR, Robinson SI, Marks RS, Johnson SH, Smadbeck JB, Halling GC, Yi ES, Wigle D, Vasmatzis G, Jen J. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib. Ann Oncol. 2016 Nov; 27 (11):2111-2117 Epub 2016 Oct 14
    View PubMed
  145. Moser J, Cassivi S, Kwon E, Mansfield AS. PS01.12: C11-Choline Positron Emission Tomography and the Detection of Primary Lung Cancers: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11 (11S):S276 Epub 2016 Oct 28
    View PubMed
  146. Kim E, Dinan M, Islam KM, Fernandes A, Schwartzberg L, Croft E, Brahmer J, Mansfield A, Hyslop T, Burke L, Crawford J. PS01.61: Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now (REVOLUTION): Registry Study in Progress: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11 (11S):S308-S309 Epub 2016 Oct 28
    View PubMed
  147. Yin P, Liu X, Mansfield AS, Harrington SM, Li Y, Yan Y, Dong H. CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1. Oncotarget. 2016 Oct 25; 7 (43):70223-70231
    View PubMed
  148. Leventakos K, Mansfield AS. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab. BioDrugs. 2016 Oct; 30 (5):397-405
    View PubMed
  149. Mansfield AS, Aubry MC, Moser JC, Harrington SM, Dronca RS, Park SS, Dong H. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol. 2016 Oct; 27 (10):1953-8 Epub 2016 Aug 08
    View PubMed
  150. Leventakos K, Kipp BR, Rumilla KM, Winters JL, Yi ES, Mansfield AS. S768I Mutation in EGFR in Patients with Lung Cancer. J Thorac Oncol. 2016 Oct; 11 (10):1798-801 Epub 2016 May 20
    View PubMed
  151. Mansfield AS, Dong H. Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy. Clin Pharmacol Ther. 2016 Sep; 100 (3):220-2 Epub 2016 May 03
    View PubMed
  152. Mansfield AS, Tafur AJ, Wang CE, Kourelis TV, Wysokinska EM, Yang P. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. J Thromb Haemost. 2016 Sep; 14 (9):1773-8 Epub 2016 Sept 09
    View PubMed
  153. Bois MC, Mansfield AS, Sukov WR, Jenkins SM, Moser JC, Sattler CA, Smith CY, Molina JR, Peikert T, Roden AC. c-Met expression and MET amplification in malignant pleural mesothelioma. Ann Diagn Pathol. 2016 Aug; 23:1-7 Epub 2016 Apr 30
    View PubMed
  154. Dronca RS, Liu X, Harrington SM, Chen L, Cao S, Kottschade LA, McWilliams RR, Block MS, Nevala WK, Thompson MA, Mansfield AS, Park SS, Markovic SN, Dong H. T cell Bim levels reflect responses to anti-PD-1 cancer therapy. JCI Insight. 2016 May 5; 1 (6)
    View PubMed
  155. Mansfield AS, Murphy SJ, Peikert T, Yi ES, Vasmatzis G, Wigle DA, Aubry MC. Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer. Clin Cancer Res. 2016 May 1; 22 (9):2177-82 Epub 2015 Dec 14
    View PubMed
  156. Leventakos K, Mansfield AS, Blackmon S, Cassivi S, Shen R, Nichols FC, Molina JR, Allen MS, Aubry MC, Wigle D. 88P: Use of brain imaging in the management of patients with lymph node negative multifocal lung cancer. J Thorac Oncol. 2016 Apr; 11: (4 Suppl)S93-4.
    View PubMed
  157. Mansfield AS, White D. Rapidly Appearing Sclerotic Vertebral Lesions in a Patient With an Infiltrative Mediastinal Mass. JAMA Oncol. 2016 Feb; 2: (2)267-8.
    View PubMed
  158. Mansfield A. The significance of pd-l1 expression in non-mall cell lung cancer Oncology Times. 2016; 38: (7)32-4.
  159. Tafur AJ, Dale G, Cherry M, Wren JD, Mansfield AS, Comp P, Rathbun S, Stoner JA. Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis. Thromb Res. 2015 Dec; 136 (6):1120-5 Epub 2015 Oct 08
    View PubMed
  160. Mansfield AS, Tafur AJ, Vulih D, Smith GL, Harris PJ, Ivy SP. Severe hepatic dysfunction is associated with venous thromboembolic events in phase 1 clinical trials. Thromb Res. 2015 Dec; 136 (6):1169-73 Epub 2015 Oct 20
    View PubMed
  161. Moser JC, Peikert T, Roden AC, Midthun DE, Mansfield AS. Spontaneous Regression of Malignant Pleural Mesothelioma in a Patient with New-Onset Inflammatory Arthropathy. Ann Am Thorac Soc 2015 Sep; 12 (9):1416-7
    View PubMed
  162. Grotz TE, Jakub JW, Mansfield AS, Goldenstein R, Enninga EA, Nevala WK, Leontovich AA, Markovic SN. Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma. Oncoimmunology. 2015 Aug; 4 (8):e1026504 Epub 2015 June 01
    View PubMed
  163. Xie D, Marks R, Zhang M, Jiang G, Jatoi A, Garces YI, Mansfield A, Molina J, Yang P. Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood Markers. J Thorac Oncol. 2015 Aug; 10 (8):1213-20
    View PubMed
  164. Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP, Mansfield AS, Furutani KM, Olivier KR, Kwon ED. PD-1 Restrains Radiotherapy-Induced Abscopal Effect. Cancer Immunol Res. 2015 Jun; 3 (6):610-9 Epub 2015 Feb 19
    View PubMed
  165. Mansfield AS, Wang L, Cunningham JM, Jen J, Kolbert CP, Sun Z, Yang P. DNA methylation and RNA expression profiles in lung adenocarcinomas of never-smokers. Cancer Genet. 2015 May; 208 (5):253-60 Epub 2014 Dec 31
    View PubMed
  166. Mansfield AS, Park SS, Dong H. Synergy of cancer immunotherapy and radiotherapy. Aging (Albany NY) 2015 Mar; 7 (3):144-5
    View PubMed
  167. Mansfield A, Peikert T. Potential Applications of Immune Checkpoint Blockade for Mesothelioma Contemporary Oncology. Feb 2015; 7(1):30-3. Epub 2015 Jan
  168. Moser JC, Pulido JS, Dronca RS, McWilliams RR, Markovic SN, Mansfield AS. The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma. Melanoma Res. 2015 Feb; 25 (1):59-63
    View PubMed
  169. Valpione S, Moser JC, Parrozzani R, Bazzi M, Mansfield AS, Mocellin S, Pigozzo J, Midena E, Markovic SN, Aliberti C, Campana LG, Chiarion-Sileni V. Development and external validation of a prognostic nomogram for metastatic uveal melanoma. PLoS One. 2015; 10 (3):e0120181 Epub 2015 Mar 17
    View PubMed
  170. Leventakos K, Mansfield AS. Reflections on immune checkpoint inhibition in non-small cell lung cancer. Transl Lung Cancer Res. 2014 Dec; 3 (6):411-3
    View PubMed
  171. Mansfield AS, Visscher DW, Hart SN, Wang C, Goetz MP, Oxvig C, Conover CA. Pregnancy-associated plasma protein-A expression in human breast cancer. Growth Horm IGF Res. 2014 Dec; 24(6):264-7.
    View PubMed
  172. Kourelis TV, Wysokinska EM, Wang Y, Yang P, Mansfield AS, Tafur AJ. Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer. Lung Cancer. 2014 Dec; 86 (3):358-62 Epub 2014 Oct 12
    View PubMed
  173. Mansfield AS, Symanowski JT, Peikert T. Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials. Lung Cancer. 2014 Nov; 86 (2):133-6 Epub 2014 Sept 01
    View PubMed
  174. Moser JC, Dronca RS, Markovic SN, Mansfield AS. Effect of beta-adrenergic blockers and other antihypertensive drugs on the risk of melanoma recurrence and death--I. Mayo Clin Proc 2014 Aug; 89 (8):1164-5
    View PubMed
  175. Meretoja TJ, Heikkila PS, Mansfield AS, Cserni G, Ambrozay E, Boross G, Zgajnar J, Perhavec A, Gazic B, Arisio R, Tvedskov TF, Jensen MB, Leidenius MH. A predictive tool to estimate the risk of axillary metastases in breast cancer patients with negative axillary ultrasound. Ann Surg Oncol. 2014 Jul; 21(7):2229-36. Epub 2014 Mar 25.
    View PubMed
  176. Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, Dong H, Kwon ED. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014 Jul; 9 (7):1036-1040
    View PubMed
  177. Degnim AC, Brahmbhatt RD, Radisky DC, Hoskin TL, Stallings-Mann M, Laudenschlager M, Mansfield A, Frost MH, Murphy L, Knutson K, Visscher DW. Immune cell quantitation in normal breast tissue lobules with and without lobulitis. Breast Cancer Res Treat. 2014 Apr; 144 (3):539-49 Epub 2014 Mar 05
    View PubMed
  178. Sio TT, Mansfield AS, Grotz TE, Graham RP, Molina JR, Que FG, Miller RC. Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis. J Hum Genet. 2014 Mar; 59 (3):124-8 Epub 2013 Dec 26
    View PubMed
  179. Phan M, John S, Casanegra AI, Rathbun S, Mansfield A, Stoner JA, Tafur AJ. Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis. J Thromb Thrombolysis. 2014; 38: (2)241-9.
    View PubMed
  180. Mansfield AS, Rabe KG, Slager SL, Schwager SM, Call TG, Brewer JD, Shanafelt TD. Skin cancer surveillance and malignancies of the skin in a community-dwelling cohort of patients with newly diagnosed chronic lymphocytic leukemia. J Oncol Pract. 2014 Jan; 10 (1):e1-4 Epub 2013 Aug 27
    View PubMed
  181. Mansfield AS, Fields AP, Jatoi A, Qi Y, Adjei AA, Erlichman C, Molina JR. Phase I dose escalation study of the PKCiota inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer. Anticancer Drugs. 2013 Nov; 24 (10):1079-83
    View PubMed
  182. Mansfield AS, Markovic SN. Inhibition of angiogenesis for the treatment of metastatic melanoma. Curr Oncol Rep. 2013 Oct; 15 (5):492-9
    View PubMed
  183. Lieser EA, Lieser EA, Croghan GA, Nevala WK, Bradshaw MJ, Markovic SN, Mansfield AS. Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions. Lung Cancer. 2013 Oct; 82 (1):63-8 Epub 2013 Aug 12
    View PubMed
  184. Bradshaw M, Mansfield A, Peikert T. The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion. Curr Oncol Rep. 2013 Jun; 15 (3):207-16
    View PubMed
  185. Mansfield AS, Jatoi A. Asphyxiation with a fentanyl patch. Case Rep Oncol. 2013 May; 6 (2):242-4 Epub 2013 May 01
    View PubMed
  186. Mansfield AS, Nevala WK, Lieser EA, Lieser EA, Leontovich AA, Markovic SN. The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. Oncoimmunology. 2013 May 1; 2 (5):e24436
    View PubMed
  187. Mansfield AS, Sukov WR, Eckel-Passow JE, Sakai Y, Walsh FJ, Lonzo M, Wiktor AE, Dogan A, Jenkins RB. Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer. Am J Clin Pathol. 2013 Feb; 139 (2):144-50
    View PubMed
  188. Mansfield AS, Heikkila P, von Smitten K, Vakkila J, Leidenius M. The presence of sinusoidal CD163(+) macrophages in lymph nodes is associated with favorable nodal status in patients with breast cancer. Virchows Arch. 2012 Dec; 461 (6):639-46 Epub 2012 Nov 13
    View PubMed
  189. Beam E, Mansfield AS, Thompson CA. 68-year-old man with neutropenic fever and upper extremity hematoma. Mayo Clin Proc. 2012 Dec; 87 (12):1226-9
    View PubMed
  190. Mansfield AS, Nevala WK, Dronca RS, Leontovich AA, Shuster L, Markovic SN. Normal ageing is associated with an increase in Th2 cells, MCP-1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF-AA between sexes. Clin Exp Immunol. 2012 Nov; 170 (2):186-93
    View PubMed
  191. Holtan SG, Mansfield AS, Creedon DJ, Nevala WK, Haluska P, Leontovich AA, Markovic SN. An organ system based approach to prognosis in advanced melanoma. Front Biosci (Elite Ed). 2012 Jun 1; 4 (8):2723-33 Epub 2012 June 01
    View PubMed
  192. Grotz TE, Mansfield AS, Jakub JW, Markovic SN. Regional lymphatic immunity in melanoma. Melanoma Res. 2012 Feb; 22(1):9-18.
    View PubMed
  193. Grotz TE, Mansfield AS, Kottschade LA, Erickson LA, Otley CC, Markovic SN, Jakub JW. In-transit melanoma: an individualized approach. Oncology (Williston Park). 2011 Dec; 25(14):1340-8.
    View PubMed
  194. Mansfield AS, Heikkila P, von Smitten K, Vakkila J, Leidenius M. Metastasis to sentinel lymph nodes in breast cancer is associated with maturation arrest of dendritic cells and poor co-localization of dendritic cells and CD8+ T cells. Virchows Arch. 2011 Oct; 459(4):391-8. Epub 2011 Sep 06.
    View PubMed
  195. Holtan SG, Dronca RS, Nevala WK, Porrata LF, Mansfield AS, Block MS, Leontovich AA, Grotz TE, Turner JD, Frisch HP, Markovic SN. The dynamic human immune response to cancer: it might just be rocket science. Immunotherapy 2011 Sep; 3 (9):1021-4
    View PubMed
  196. Mansfield AS, Holtan SG, Grotz TE, Allred JB, Jakub JW, Erickson LA, Markovic SN. Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. Mod Pathol. 2011 Apr; 24 (4):487-94 Epub 2010 Dec 10
    View PubMed
  197. Winter JM, Narang AK, Mansfield AS, Herman JM, Cameron JL, Laheru D, Eckhauser FE, Olson MT, Hruban RH, Miller RC, Andersen DK. Resectable pancreatic small cell carcinoma. Rare Tumors. 2011 Mar 30; 3 (1):e5
    View PubMed
  198. Mansfield A, Tafur A, Smithedajkul P, Corsini M, Quevedo F, Miller R. Mayo Clinic experience with very rare exocrine pancreatic neoplasms. Pancreas. 2010 Oct; 39(7):972-5.
    View PubMed
  199. Mansfield A, Larson B, Stafford SL, Shives TC, Haddock MG, Dingli D. Angiomatoid fibrous histiocytoma in a 25-year-old male. Rare Tumors. 2010 Jun 30; 2 (2):e20 Epub 2010 June 30
    View PubMed
  200. Kayastha GK, Gurung P, Acharya PK, Paudyal BP, Hayes B, Zimmerman M, Karki A, Mansfield AS. Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor. BMC Blood Disord. 2010; 10:8. Epub 2010 Dec 07.
    View PubMed
  201. Cook-Norris RH, Mansfield AS, Michaels JD, Davis MD. Hydroxycarbamide-induced dermopathy. Am J Hematol. 2010 Jan; 85(1):75-6.
    View PubMed
  202. Mansfield AS, Qian Q. 71-year-old man with chronic kidney failure and sudden change of mental status. Mayo Clin Proc. 2009 Nov; 84(11):e5-8.
    View PubMed
  203. Mansfield AS, Markovic SN. Novel therapeutics for the treatment of metastatic melanoma. Future Oncol. 2009 May; 5 (4):543-57
    View PubMed
  204. Mansfield AS, Heikkila PS, Vaara AT, von Smitten KA, Vakkila JM, Leidenius MH. Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer. 2009; 9:231. Epub 2009 Jul 15.
    View PubMed
PST-20227292